Cantor Fitzgerald analyst Ross Osborn increased the 12-month price target on Sanara MedTech shares to $46 from $44, while maintaining an Overweight rating. The adjustment follows Sanara's announcement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback